I'm LongbridgeAI, I can summarize articles.U.S. stocks saw mixed trading with the Dow Jones rising over 200 points on Wednesday. Estee Lauder shares surged 17.7% after reporting better-than-expected Q4 results and positive FY27 guidance. Moderna jumped nearly 100% following positive Phase 3 trial results announced jointly with Merck, which also rose 11.3%. Other notable gainers included Marvell Technology, BioNTech, and Twist Bioscience.
U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Wednesday.
Shares of Estee Lauder Companies Inc (NYSE:EL) rose sharply after the company reported better-than-expected fourth-quarter financial results and issued its FY27 sales guidance with its midpoint above estimates.
Adjusted earnings were 39 cents per share, beating the analyst estimate of 32 cents. The Middle East conflict reduced adjusted earnings by 5 cents per share. However, tariff refunds provided a 7-cent benefit.
Sales rose 6% year over year to $3.63 billion, beating the $3.54 billion analyst estimate. Organic net sales increased 5%.
Estee Lauder shares jumped 17.7% to $99.15 on Wednesday.
Here are some other big stocks recording gains in today’s session.
- Moderna Inc (NASDAQ:MRNA) shares jumped 99.6% to $125.70 after the company and Merck announced topline results from the Phase 3 INTerpath-001 trial met its primary and a key secondary endpoint.
- Maravai Lifesciences Holdings Inc (NASDAQ:MRVI) gained 33.2% to $7.64.
- BioNTech SE – ADR (NASDAQ:BNTX) surged 19.6% to $111.01.
- Eikon Therapeutics Inc (NASDAQ:EIKN) gained 19.2% to $13.89.
- Twist Bioscience Corp (NASDAQ:TWST) gained 18.4% to $137.47.
- Prime Medicine, Inc (NASDAQ:PRME) gained 14.4% to $3.49. BMO Capital analyst David Lebowitz initiated coverage on Prime Medicine with an Outperform rating and announced a price target of $9.
- Algoma Steel Group Inc (NASDAQ:ASTL) rose 13.1% to $4.62.
- Tempus AI Inc (NYSE:TEM) gained 13.1% to $55.82.
- DRDGOLD Ltd (NYSE:DRD) shares jumped 12.5% to $27.36.
- Pilgrims Pride Corp (NYSE:PPC) gained 12.1% to $31.93.
- Merck & Co Inc (NYSE:MRK) rose 11.3% to $150.43 after the company announced topline results from the Phase 3 INTerpath-001 trial. The trial met its primary and key secondary endpoint.
- Aris Mining Corp (NYSE:ARIS) gained 10.6% to $19.43.
- Editas Medicine Inc (NASDAQ:EDIT) rose 10.3% to $3.18.
- Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares surged 9.8% to $7.17.
- Coty Inc (NYSE:COTY) gained 9.6% to $3.00.
- Iovance Biotherapeutics Inc (NASDAQ:IOVA) gained 7.8% to $7.58.
- 10X Genomics Inc (NASDAQ:TXG) surged 7.7% to $59.92.
- Marvell Technology Inc (NASDAQ:MRVL) gained 7.4% to $232.04 following an SEC Form 8-K filing disclosing a major commercial agreement and warrant deal with Google.
- Crispr Therapeutics AG (NASDAQ:CRSP) rose 6.5% to $56.43.
Photo via Shutterstock